cerus corporation american multinational biotechnology company headquartered concord california develops provides treatment system pathogenreduce human blood products healthcare industry hematologist laurence corash developed novel method inactivating hiv particles contained donated blood plasma using ultraviolet lights continued building prototypes help colleagues ucsan francisco school medicine together chemist john e hearst founded company cerus technologies inc september later renamed cerus corporation initial sec companys proprietary technology called helinx conceived corash method protect patients hivtainted plasma platelet donations growing aids epidemic two blood components found suitable treat exvivo isolation companys uva light process due naturally translucent properties uv exposure process works intentionally damaging dna rna material foreign virus bacteria might present remaining harmless donated blood plasma platelets contains rna december helinx process incorporated medical device called intercept platelet blood screening system cerus entered agreement baxter international inc jointly commercialize device european union healthcare market gain regulatory approvals cerus announced acquired baxters shared commercial rights intercept blood system plasma platelets also revealed working expanding system treat red blood cells opaque harder treat cerus later entered another commercialization agreement grifols sa market operate products blood centers spain intercept blood system platelets received eu ce mark class iii certification us fda premarket approval december march fda granted expanded modification existing approval also treat platelets suspended plasma platelet ce mark reapproved modification extend platelet storage seven days previously five intercept blood system plasma received eu ce mark certification november us fda premarket approval december cerus also received certification iso blood plasma platelet products august cerus received us fda emergency use authorization treat donated convalescent plasma recovered patients purpose giving investigative antibody immunotherapy transfusions patients suffering needed products primary purpose guarantee clean supply blood products deactivate known unknown pathogens minimal added effort helinx technology intercept system shown effective several types viruses universally effective due kinds pathogens rna dna resilient process hepatitis human parvovirus bacterial spores studies shown system effective neutralizing hiv hepatitis b hepatitis c west nile virus cov mers cov zika dengue fever also touted able render certain bacteriacitation needed unable addition pathogen neutralization clinical trials west africa test effectiveness using intercept system treat convalescent plasma ebola survivors administering treated plasma patients still fighting infection convalescent treatments using intercept also applied ebola survivor plasma donations emory university platelet donations puerto rico dengue fever chikungunya infections population similarly us fda granted emergency use intercept sterilize convalescent patient plasma although us medical community harbors disagreements whether approach provide effective relief intercept systems use multiple eu healthcare settings however us market gained traction among blood centers due added costs top ample domestic supply prescreened clean blood plasma platelet developing countries lower levels health care access product finding greater clinical humanitarian trial opportunities due high rates collecting using unsafe donated whole blood low access plasma platelet separating equipment low supply screening height zika virus spread cerus technology supplied designated blood center rio de janeiro brazil use ensuring clean blood supply competing athletes rio olympic httpsenwikipediaorgwikiceruscorporation